FDA Moves On NDA For First US OTC Birth Control, Scheduling Joint Ad Comm Meeting

The US market is one step closer to its first birth control pill available without a prescription as the US Food and Drug Administration announces a joint advisory committee meeting to review a new drug application for Rx-to-OTC switch of HRA Pharma’s Opill (0.075-mg norgestrel).

Published on 13 September in the Federal Register, FDA says it will hold a virtual meeting of the Nonprescription Drugs Advisory Committee and the Obstetrics,